Spots Global Cancer Trial Database for Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety Study of Imexon Treatment of Patients With Metastatic or Disseminated Malignancy
Official Title: A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Administered Daily for 5 Days Every 3 Weeks to Patients With Metastatic Cancer or Disseminated Malignancy
Study ID: NCT00327223
Conditions
Interventions
Study Description
Brief Summary: AMP-011 is a Phase 1 study designed to extend the understanding of the toxicity and pharmacology of imexon by investigating a schedule of daily treatment for 5 days every three weeks. The objective of the study is to determine the maximally tolerated dose, the pharmacokinetics, and the toxicity of the drug on the designated schedule.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
US Oncology Indiana, Indianapolis, Indiana, United States
US Oncology Albany, New York Oncology, Albany, New York, United States
Investigational Site 014, Temple, Texas, United States
US Oncology, Tyler Cancer Center, Tyler, Texas, United States
Contact Details
Name: Evan Hersh, MD
Affiliation: AmpliMed Corporation
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
